Market Overview

UPDATE: Credit Suisse Initiates Genomic Health at Outperform on Growth Potential

Related GHDX
Genomic Health's Oncotype DX Redefines Breast Cancer Therapy - Analyst Blog
Genomic Health Up on Fresh Cancer Study Data - Analyst Blog

Credit Suisse initiated coverage on Genomic Health (NASDAQ: GHDX) with an Outperform rating and a $43 price target.

Credit Suisse said, "Genomic Health's stock has steadily appreciated over the past two years due to the success of its Oncotype DX cancer assays. We believe that the trend should continue as the company captures incremental market share with its already-established tests in breast and colon cancer and launches tests in new markets such as prostate cancer."

Genomic Health closed at $36.15 on Monday.

Posted-In: Credit SuisseAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Most Popular

Related Articles (GHDX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free